View Older Stories View More Recent Stories
-
Form N-PX DEERFIELD MANAGEMENT For: Jun 30
-
BioCentury to Host Grand Rounds in Nashville: A Premier Gathering of Drug Development Thought Leaders at the Interface of Academia and Industry
-
Neomorph Announces Appointment of Dr. Peter Lebowitz, M.D., Ph.D. to its Board of Directors
-
Form 13F-HR DEERFIELD MANAGEMENT For: Jun 30
-
Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates
-
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
-
MMI Completes World’s First Robotic Preclinical Study in Neurosurgery with Symani® Surgical System
-
Publication of Strongly Positive Findings Demonstrate Benefits of Innovative Jewel® Patch Wearable Cardioverter Defibrillator for Patients at Risk of Sudden Cardiac Arrest
-
Day One Biopharmaceuticals (DAWN) Announces 10.55M Share Offering at $14.50/sh
-
Day One Announces Oversubscribed $175.0 Million Private Placement
-
Form 4 BiomX Inc. For: Jul 11 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Jaguar Gene Therapy to Initiate Inaugural Pediatric Clinical Trial Targeting a Genetic Form of Autism Spectrum Disorder and Phelan-McDermid Syndrome
-
MMI Builds Global Momentum with Multiple Distribution Agreements and Regulatory Approvals
-
Element Science Receives Prestigious International Red Dot Design Award for Innovative Jewel® Patch Wearable Cardioverter Defibrillator
-
Endologix Appoints Graham Phillips as Chief Operating Officer
-
Elion Therapeutics Closes $81 Million Series B Funding Round Led by Deerfield Management and AMR Action Fund
-
Mereo BioPharma (MREO) Prices 12.53M Share Offering at $3.99/sh
-
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
-
Leo Cancer Care to Use Series C Financing to Grow Global Footprint
-
Advanced Medicine Partners Executes Additional $32 Million Financing Agreement led by Deerfield Management, Appoints Two New Board Members
-
Deerfield Management Welcomes Frank Nestle, MD, FMedSci, as Partner and Chief Executive Officer of Therapeutic Discovery and Development
-
Cohere Health, Medical Mutual, and Rhyme Partner on Utilization Management Transformation
-
Form 4 Larimar Therapeutics, For: May 29 Filed by: DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
-
Cure® Unveils US Biotech Industry Benchmark Report 2024: Dark Days of 2023 are Over
-
Adela to Present Data Supporting Use of its Tissue-Agnostic MRD Assay for Recurrence Prediction and Monitoring in Patients with Head & Neck Cancer at the American Society of Clinical Oncology 2024
-
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
-
BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates
-
Meditrina Announces 510(k) Clearance for Gen 2 Bipolar RF Hysteroscopy System and Aveta Glo Bipolar RF Device
-
Element Science Appoints Lee Smith, Jr. as the Company’s First Head of Commercial
-
Form 13F-HR DEERFIELD MANAGEMENT For: Mar 31
-
Cohere Health Launches Early Trend Signal Intelligence to Predict Utilization Trends Earlier than Claims-based Methods
-
One-Year Results of the DETOUR2 Trial published in the Journal of Vascular Surgery (JVS)
-
Apertura Gene Therapy Showcases Advancements in Capsid Engineering Platform in Presentations at ASGCT Annual Meeting
-
R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new President and CEO
-
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
-
Deerfield Management and Deerfield Foundation Announce Second Annual AML Summit and Recipients of American Society of Hematology (ASH) Peter Steelman Scholar Award
-
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
-
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
-
MMI Completes First Symani® Clinical Cases in the U.S. Following FDA Commercial Authorization
-
MMI Completes First Symani® Clinical Cases in the U.S. Following FDA Commercial Authorization
-
Lumeris Completes $100M Equity Growth Capital Investment Round
-
Genscience and Deerfield Management Announce Nature Publication Reporting Positive Impact of Genetic Evidence to Aid Discovery of More Effective Drug Targets
-
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
-
Cullinan Therapeutics (CGEM) Announces $280M Placement at $19/sh
-
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
-
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.
-
CURE OPENS XSEED AWARD APPLICATIONS TO SUPPORT UNDERFUNDED AND UNDERREPRESENTED NYC LIFE SCIENCE STARTUPS WITH UP TO $500,000
-
Adela Presents Data Demonstrating Ability of Tissue-Agnostic MRD Assay to Predict Recurrence in Head & Neck Cancer at the American Association for Cancer Research Annual Meeting 2024
-
MMI Receives FDA Authorization to Commercialize Symani® Surgical System in the U.S.
-
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
